News articles about Kitov Pharmaceuticals (NASDAQ:KTOV) have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kitov Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.4047441585534 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Kitov Pharmaceuticals (NASDAQ:KTOV) traded down $0.02 on Thursday, reaching $2.34. The company’s stock had a trading volume of 113,400 shares, compared to its average volume of 168,150. Kitov Pharmaceuticals has a 52 week low of $1.27 and a 52 week high of $3.49.
Separately, HC Wainwright raised Kitov Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Tuesday, November 21st.
Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
Receive News & Ratings for Kitov Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.